Cannabis

In the 12th PD year, the patient has learned to be minimalist and patient and to avoid running after the miracle molecule of the month. So with cannabis the first learning step taken was to start with a pure CBD tincture at a low initial dosage of 10 mg. The experience was positive in two respects: Subjectively, the CBD makes the patient mellower and more relaxed without any stony edges or even any foreground awareness of an altered state. Objectively, there are two definite and measurable benefits: taken in the morning, CBD dampens the higher-frequency tremors in the hands, improving typing from very-terrible to merely bad, making the patient more functional. And it has essentially eliminated osteoarthritis, which formerly appeared episodically for 7-10 days at a time at unpredictable intervals. Given that every other substance recommended for “treating” osteoarthritis provided no more than palliative relief, this is a big deal for the patient.

Other cannabis explorations lie ahead, with further benefit expected.

I’m only 5 months in. My balance is horrible and I’ve fallen a few times. No tremor. I have muscle weakness and stiffness, mainly in my fingers and toes. I feel like I’m walking through molasses all day and I have 0 stamina. It’s definitely a nuisance. I got medical marijuana and use it for sleep. That’s a big improvement.

The expert panel discusses the use of medical marijuana, particularly CBD (Cannabidiol), for Parkinson's patients. They note that many patients use CBD-dominant products because they are less likely to cause psychotic effects compared to THC (Tetrahydrocannabinol). The panel emphasizes that CBD products are generally considered safe, but they are not FDA-regulated, so the actual contents may not match the label. They also mention that CBD might have a strong placebo effect, partly due to its trendy nature and past legal restrictions. The effectiveness of CBD beyond placebo remains uncertain.

The expert highlights that while cannabis is a natural product, it is not free from side effects. Prior trials have shown issues such as low blood pressure, dizziness, balance problems, cognitive effects, and even worsening depression or apathy. Legal and regulatory barriers have slowed research progress, even in states like Colorado where cannabis is legal. The expert also notes challenges in studying cannabis, such as determining the best study design, quality control, and dosage, especially when comparing purified compounds like CBD and THC to plant-based forms. Sponsorship and funding for research are additional hurdles.

This paper systematically reviewed and analyzed studies on the effects of cannabis as a treatment for Parkinson's disease. It included five randomized controlled studies and eighteen non-randomized studies to evaluate the potential benefits and risks of cannabis use in Parkinson's patients.

The review found no strong evidence to recommend cannabis as a treatment for Parkinson's disease. However, it identified potential benefits in reducing tremors, anxiety, pain, and improving sleep quality and overall quality of life for patients.

For someone living with Parkinson's or caring for someone with the condition, this paper suggests that cannabis might help with specific symptoms like tremors and anxiety, but it is not a proven treatment. It highlights the need for more research to confirm these potential benefits.

The paper is a systematic review published in the Journal of Parkinson's Disease, which is a reputable source in the field. However, the reliability is limited by the lack of well-designed randomized studies on this topic.

This paper systematically reviewed and analyzed studies on the use of medical cannabis and its derivatives for treating motor symptoms in Parkinson's disease. It included 15 studies, such as randomized controlled trials (RCTs) and observational studies, to evaluate changes in motor function, dyskinesia, and safety.

The analysis found that while observational studies often reported symptom improvement, controlled studies, including a meta-analysis of three RCTs with 83 patients, showed no significant improvement in motor symptoms. The intervention was generally well-tolerated, but the studies had a high risk of bias, and only one study showed significant improvement in dyskinesia.

For people with Parkinson's or their caregivers, this paper suggests that while cannabis may subjectively help some individuals, there is not enough strong evidence to recommend it for motor symptom treatment. It highlights the need for more rigorous research before cannabis can be considered a reliable treatment option.

The paper is a systematic review, which is a high level of evidence, but it notes that the included studies had a high risk of bias. Published in a reputable journal, the findings are relevant but limited by the quality of the underlying data.